{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:51:36Z","timestamp":1791460296704,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare, aggressive kidney cancer with no established standard of care. This phase 2 trial (NCT05877820) assessed first-line tislelizumab plus lenvatinib in advanced FH-RCC (\n                    <jats:italic>N<\/jats:italic>\n                    \u2009=\u200920). The primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR) and safety. After a median follow-up of 20.2 months, ORR was 95% (95% CI 75.1\u201399.9), and DCR was 100% (95% CI 83.2\u2013100). Median PFS was 20.7 months (95% CI 17.8\u2013NR), median DOR was 19.2 months (95% CI 16.3\u2013NR) and 2-year OS rate was 89.7% (95% CI 77.2\u2013100). Grade \u22653 treatment-related adverse events occurred in 45% of patients. Circulating succinyl-adenosine and succinic-cysteine tracked radiographic tumor burden in 80% of patients. Limitations include the single-center, single-arm design, and limited sample size. These results support tislelizumab plus lenvatinib as a potential first-line option for advanced FH-RCC, with favorable antitumor activity and manageable safety profile. Circulating succinate-modifying metabolites may complement response monitoring but require further validation.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-77615-9","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:33:55Z","timestamp":1788813235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2326-3220","authenticated-orcid":false,"given":"Wen","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1984-3624","authenticated-orcid":false,"given":"Yunze","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4400-9472","authenticated-orcid":false,"given":"Guiqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-8813","authenticated-orcid":false,"given":"Wenwen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6274-6404","authenticated-orcid":false,"given":"Wei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2126-7335","authenticated-orcid":false,"given":"Jiahua","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1789-9108","authenticated-orcid":false,"given":"Guangyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5346-4111","authenticated-orcid":false,"given":"Liang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-9941","authenticated-orcid":false,"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9046-1519","authenticated-orcid":false,"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"77615_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch, H. et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur. Urol. 82, 458\u2013468 (2022).","journal-title":"Eur. Urol."},{"key":"77615_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semcdb.2019.05.002","volume":"98","author":"C Schmidt","year":"2020","unstructured":"Schmidt, C., Sciacovelli, M. & Frezza, C. Fumarate hydratase in cancer: a multifaceted tumour suppressor. Semin Cell Dev. Biol. 98, 15\u201325 (2020).","journal-title":"Semin Cell Dev. Biol."},{"key":"77615_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.6004\/jnccn.2024.0008","volume":"22","author":"RJ Motzer","year":"2024","unstructured":"Motzer, R. J. et al. NCCN guidelines(R) insights: kidney cancer, version 2.2024. J. Natl. Compr. Canc Netw. 22, 4\u201316 (2024).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"77615_CR4","doi-asserted-by":"publisher","first-page":"5004","DOI":"10.1200\/JCO.2020.38.15_suppl.5004","volume":"38","author":"R Srinivasan","year":"2020","unstructured":"Srinivasan, R. et al. Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer. J. Clin. Oncol. 38, 5004 (2020).","journal-title":"J. Clin. Oncol."},{"key":"77615_CR5","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1056\/NEJMoa2200900","volume":"392","author":"R Srinivasan","year":"2025","unstructured":"Srinivasan, R. et al. Bevacizumab and erlotinib in hereditary and sporadic papillary kidney cancer. N. Engl. J. Med. 392, 2346\u20132356 (2025).","journal-title":"N. Engl. J. Med."},{"key":"77615_CR6","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","volume":"384","author":"TK Choueiri","year":"2021","unstructured":"Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829\u2013841 (2021).","journal-title":"N. Engl. J. Med."},{"key":"77615_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","volume":"384","author":"R Motzer","year":"2021","unstructured":"Motzer, R. et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384, 1289\u20131300 (2021).","journal-title":"N. Engl. J. Med."},{"key":"77615_CR8","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"77615_CR9","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","volume":"35","author":"XQ Yan","year":"2024","unstructured":"Yan, X. Q. et al. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. Ann. Oncol. 35, 190\u2013199 (2024).","journal-title":"Ann. Oncol."},{"key":"77615_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eururo.2022.05.029","volume":"83","author":"Y Xu","year":"2023","unstructured":"Xu, Y. et al. Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in fh-deficient renal cell carcinoma. Eur. Urol. 83, 163\u2013172 (2023).","journal-title":"Eur. Urol."},{"key":"77615_CR11","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","volume":"24","author":"L Albiges","year":"2023","unstructured":"Albiges, L. et al. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 24, 881\u2013891 (2023).","journal-title":"Lancet Oncol."},{"key":"77615_CR12","doi-asserted-by":"publisher","first-page":"e165028","DOI":"10.1172\/JCI165028","volume":"133","author":"L Zheng","year":"2023","unstructured":"Zheng, L. et al. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma. J. Clin. Invest. 133, e165028 (2023).","journal-title":"J. Clin. Invest."},{"key":"77615_CR13","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","volume":"27","author":"G Sun","year":"2021","unstructured":"Sun, G. et al. Integrated molecular characterization of fumarate hydratase-deficient renal cell carcinoma. Clin. Cancer Res. 27, 1734\u20131743 (2021).","journal-title":"Clin. Cancer Res."},{"key":"77615_CR14","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1158\/1078-0432.CCR-22-1279","volume":"28","author":"P Dong","year":"2022","unstructured":"Dong, P. et al. Genomic characteristics and single-cell profiles after immunotherapy in fumarate hydratase-deficient renal cell carcinoma. Clin. Cancer Res. 28, 4807\u20134819 (2022).","journal-title":"Clin. Cancer Res."},{"key":"77615_CR15","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.21.01944","volume":"40","author":"CH Lee","year":"2022","unstructured":"Lee, C. H. et al. Phase II Trial of cabozantinib plus nivolumab in patients with non-clear-cell renal cell carcinoma and genomic correlates. J. Clin. Oncol. 40, 2333\u20132341 (2022).","journal-title":"J. Clin. Oncol."},{"key":"77615_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.eururo.2024.04.025","volume":"86","author":"KN Fitzgerald","year":"2024","unstructured":"Fitzgerald, K. N. et al. Cabozantinib plus nivolumab in patients with non-clear cell renal cell carcinoma: updated results from a phase 2 trial. Eur. Urol. 86, 90\u201394 (2024).","journal-title":"Eur. Urol."},{"key":"77615_CR17","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/jamaoncol.2025.2497","volume":"11","author":"X Zhang","year":"2025","unstructured":"Zhang, X. et al. Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: a phase 2 nonrandomized clinical trial. JAMA Oncol. 11, 1169\u20131177 (2025).","journal-title":"JAMA Oncol."},{"key":"77615_CR18","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2021.04.009","volume":"151","author":"L Carril-Ajuria","year":"2021","unstructured":"Carril-Ajuria, L. et al. Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. Eur. J. Cancer 151, 106\u2013114 (2021).","journal-title":"Eur. J. Cancer"},{"key":"77615_CR19","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","volume":"27","author":"JP Gleeson","year":"2021","unstructured":"Gleeson, J. P. et al. Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma. Clin. Cancer Res. 27, 2910\u20132919 (2021).","journal-title":"Clin. Cancer Res."},{"key":"77615_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1158\/0008-5472.CAN-20-2426","volume":"82","author":"Y Adachi","year":"2022","unstructured":"Adachi, Y. et al. Inhibition of FGFR reactivates IFNgamma signaling in tumor cells to enhance the combined antitumor activity of lenvatinib with Anti-PD-1 antibodies. Cancer Res 82, 292\u2013306 (2022).","journal-title":"Cancer Res"},{"key":"77615_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/2045-824X-6-18","volume":"6","author":"Y Yamamoto","year":"2014","unstructured":"Yamamoto, Y. et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR\/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc. Cell 6, 18 (2014).","journal-title":"Vasc. Cell"},{"key":"77615_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"77615_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","volume":"38","author":"YB Chen","year":"2014","unstructured":"Chen, Y. B. et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am. J. Surg. Pathol. 38, 627\u2013637 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"77615_CR24","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/PAS.0000000000000626","volume":"40","author":"B Buelow","year":"2016","unstructured":"Buelow, B. et al. Immunohistochemistry for 2-succinocysteine (2SC) and Fumarate Hydratase (FH) in cutaneous leiomyomas may aid in identification of patients with HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome). Am. J. Surg. Pathol. 40, 982\u2013988 (2016).","journal-title":"Am. J. Surg. Pathol."},{"key":"77615_CR25","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1097\/PAS.0000000000000520","volume":"39","author":"NM Joseph","year":"2015","unstructured":"Joseph, N. M. et al. Morphology and Immunohistochemistry for 2SC and FH aid in detection of fumarate hydratase gene aberrations in uterine leiomyomas from young patients. Am. J. Surg. Pathol. 39, 1529\u20131539 (2015).","journal-title":"Am. J. Surg. Pathol."},{"key":"77615_CR26","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, Md: U.S. Department of Health and Human Services, (National Institutes of Health, 2017)."},{"key":"77615_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control Clin. Trials"},{"key":"77615_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60317-z","volume":"16","author":"K Liu","year":"2025","unstructured":"Liu, K. et al. Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial. Nat. Commun. 16, 5069 (2025).","journal-title":"Nat. Commun."},{"key":"77615_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41955-7","volume":"14","author":"M Yan","year":"2023","unstructured":"Yan, M. et al. Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial. Nat. Commun. 14, 6272 (2023).","journal-title":"Nat. Commun."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77615-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77615-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:02:03Z","timestamp":1791457323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77615-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77615"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77615-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8771803\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10591"}}